167 related articles for article (PubMed ID: 3922776)
1. N-methyl,N-propargyl-2-aminotetralins:novel dopamine agonists with monoamine oxidase inhibiting properties.
Hazelhoff B; De Vries JB; Dijkstra D; Mulder TB; Horn AS
Eur J Pharmacol; 1985 Feb; 109(2):229-40. PubMed ID: 3922776
[TBL] [Abstract][Full Text] [Related]
2. Neuropharmacological profile of a new series of dopamine agonists: N-n-propyl-hexahydronaphthoxazines.
Hazelhoff B; De Vries JB; Dijkstra D; Mulder TB; Timmermans PB; Wynberg H; Horn AS
Eur J Pharmacol; 1986 May; 124(1-2):93-106. PubMed ID: 3720849
[TBL] [Abstract][Full Text] [Related]
3. In vivo dopamine autoreceptor selectivity appears to be critically dependent upon the aromatic hydroxyl position in a series of N,N-disubstituted 2-aminotetralins.
Van Oene JC; De Vries JB; Dijkstra D; Renkema RJ; Tepper PG; Horn AS
Eur J Pharmacol; 1984 Jun; 102(1):101-15. PubMed ID: 6434327
[TBL] [Abstract][Full Text] [Related]
4. Further in vitro and in vivo studies with the putative presynaptic dopamine agonist N,N-dipropyl-7-hydroxy-2-aminotetralin.
Mulder TB; de Vries JB; Dijkstra D; Wiechers JW; Grol CJ; Horn AS
Naunyn Schmiedebergs Arch Pharmacol; 1987 Nov; 336(5):494-501. PubMed ID: 2830544
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological profiles of three new, potent and selective dopamine receptor agonists: N-0434, N-0437 and N-0734.
Van der Weide J; De Vries JB; Tepper PG; Horn AS
Eur J Pharmacol; 1986 Jun; 125(2):273-82. PubMed ID: 3743637
[TBL] [Abstract][Full Text] [Related]
6. Further characterization of structural requirements for agonists at the striatal dopamine D2 receptor and a comparison with those at the striatal dopamine D1 receptor. Studies with a series of monohydroxyaminotetralins on acetylcholine release from rat striatum.
Seiler MP; Markstein R
Mol Pharmacol; 1984 Nov; 26(3):452-7. PubMed ID: 6238231
[TBL] [Abstract][Full Text] [Related]
7. Relative selectivity of 6,7-dihydroxy-2-dimethylaminotetralin, N-n-propyl-3-(3-hydroxyphenyl)piperidine, N-n-propylnorapomorphine and pergolide as agonists at striatal dopamine autoreceptors and postsynaptic dopamine receptors.
Claustre Y; Fage D; Zivkovic B; Scatton B
J Pharmacol Exp Ther; 1985 Feb; 232(2):519-25. PubMed ID: 2857197
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological profile of a chromanamine analogue (DP-6OH-3CA) of the selective presynaptic dopamine agonist N,N-dipropyl-7-hydroxy-2-aminotetralin.
Vermue NA; Dijkstra D; Horn AS
J Pharm Pharmacol; 1988 Aug; 40(8):574-7. PubMed ID: 2907015
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological profiles of the putative dopamine autoreceptor agonists 3-PPP and TL-99.
Martin GE; Haubrich DR; Williams M
Eur J Pharmacol; 1981 Nov; 76(1):15-23. PubMed ID: 7318920
[TBL] [Abstract][Full Text] [Related]
10. Effect of non-catecholic 2-aminotetralin derivatives on dopamine metabolism in the rat striatum.
Feenstra MG; Rollema H; Dijkstra D; Grol CJ; Horn AS; Westerink BH
Naunyn Schmiedebergs Arch Pharmacol; 1980 Sep; 313(3):213-9. PubMed ID: 7432553
[TBL] [Abstract][Full Text] [Related]
11. The neuropharmacological profile of N-methyl-N-propargyl-2-aminotetralin: a potent monoamine oxidase inhibitor.
Hazelhoff B; De Vries JB; Dijkstra D; de Jong W; Horn AS
Naunyn Schmiedebergs Arch Pharmacol; 1985 Jul; 330(1):50-8. PubMed ID: 2413370
[TBL] [Abstract][Full Text] [Related]
12. A pharmacological comparison of 6,7-dihydroxy-2-dimethylaminotetralin (TL-99) and N-n-propyl-3-(3-hydroxyphenyl)piperidine with (3-PPP) selected dopamine agonists.
Martin GE; Williams M; Haubrich DR
J Pharmacol Exp Ther; 1982 Nov; 223(2):298-304. PubMed ID: 6813451
[No Abstract] [Full Text] [Related]
13. (+)-AJ 76 and (+)-UH 232: central stimulants acting as preferential dopamine autoreceptor antagonists.
Svensson K; Johansson AM; Magnusson T; Carlsson A
Naunyn Schmiedebergs Arch Pharmacol; 1986 Nov; 334(3):234-45. PubMed ID: 2880302
[TBL] [Abstract][Full Text] [Related]
14. Resolved cis- and trans-2-amino-5-methoxy-1-methyltetralins: central dopamine receptor agonists and antagonists.
Johansson AM; Arvidsson LE; Hacksell U; Nilsson JL; Svensson K; Carlsson A
J Med Chem; 1987 Apr; 30(4):602-11. PubMed ID: 3560156
[TBL] [Abstract][Full Text] [Related]
15. N-0437: a selective D-2 dopamine receptor agonist in in vitro and in vivo models.
Van der Weide J; De Vries JB; Tepper PG; Krause DN; Dubocovich ML; Horn AS
Eur J Pharmacol; 1988 Mar; 147(2):249-58. PubMed ID: 3130270
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological profile of N,N dipropyl-8-hydroxy-3-chromanamine, an oxygen isostere of the dopamine agonist N,N dipropyl-5-hydroxy-2-aminotetralin with enhanced presynaptic selectivity.
Vermue NA; Kaptein B; Tepper PG; de Vries JB; Horn AS
Arch Int Pharmacodyn Ther; 1988; 293():37-56. PubMed ID: 3421784
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the dopaminergic effects of apomorphine and (-)-N-n-propylnorapomorphine.
Menon MK; Clark WG; Neumeyer JL
Eur J Pharmacol; 1978 Nov; 52(1):1-9. PubMed ID: 569056
[TBL] [Abstract][Full Text] [Related]
18. The enantiomers of the D-2 dopamine receptor agonist N-0437 discriminate between pre- and postsynaptic dopamine receptors.
Van der Weide J; Tendijck ME; Tepper PG; De Vries JB; Dubocovich ML; Horn AS
Eur J Pharmacol; 1988 Feb; 146(2-3):319-26. PubMed ID: 2836210
[TBL] [Abstract][Full Text] [Related]
19. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity.
Kikuchi T; Tottori K; Uwahodo Y; Hirose T; Miwa T; Oshiro Y; Morita S
J Pharmacol Exp Ther; 1995 Jul; 274(1):329-36. PubMed ID: 7616416
[TBL] [Abstract][Full Text] [Related]
20. Presynaptic inhibition of dopamine synthesis in rat striatal tissue by enantiomeric mono- and dihydroxyaporphines.
Booth RG; Baldessarini RJ; Kula NS; Gao Y; Zong R; Neumeyer JL
Mol Pharmacol; 1990 Jul; 38(1):92-101. PubMed ID: 1973525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
